Related Experiment Video
Updated: Jun 5, 2025
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
SLNP-based CDK4- targeted nanotherapy against glioblastoma
Uzma Ghani1, Fareeha Khalid Ghori1, Muhammad Usman Qamar2,3
1Molecular Immunology Laboratory, Department of Healthcare Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan.
Introduction:
Glioblastoma is a grade IV solid brain tumor and has a 15-month survival rate even after treatment. Glioblastoma development is heavily influenced by retinoblastoma protein (pRB) pathway changes. The blood-brain barrier, drug resistance, and severe toxicity of Temozolamide are key obstacles in treating glioblastoma. Innovative treatments targeting the pRB pathway with efficient delivery vehicles are required to treat glioblastoma.
Methods:
For this purpose, a library of 691 plant extracts previously tested in vitro for anti-cancerous, anti inflammatory, and anti-proliferative characteristics was created after thorough literature investigations. Compounds were docked against pRB pathway protein ligands using molecular operating environment and chimera. Their nuclear structure and drug-like properties were predicted through Lipinski rule and density functional theory analysis. Physio-chemical characterizations of naked and drug-encapsulated SLNPs assessed size, stability, entrapment efficiency, and drug release rate. Anti-cancer potential of drug and drug- loaded SLNPs was evaluated using U87, U251, and HEK cell lines. Formulations were tested for cancer cell metastatic potential using cell migration assays.
Results:
Silymarin (Sil) was identified as the most potent compound against CDK4, which was then encapsulated in stearic acid solid lipid nanoparticles (SLNP-Sil). Sil showed decreased cell viability 72 h after treatment against both U87 and U251 cell lines but had negligible cytotoxic effect on HEK-293. IC50 value of Sil was 155.14 µM for U87 and 195.93 µM for U251. Sil and SLNP-Sil effectively inhibited U87 and U251 cell migration 24 h after treatment.
Discussion:
Our results indicated that Sil and SLNP-Sil are promising therapeutic approaches against glioblastoma and merit in vivo experimental verification using orthotropic xenograft mouse models against glioblastoma.
Insights
Silymarin, a plant extract, shows potent anti-glioblastoma activity by inhibiting cancer cell growth and migration. Encapsulating silymarin in nanoparticles enhances its therapeutic potential for treating this aggressive brain tumor.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis.
- Current treatments face challenges like drug resistance and toxicity.
- The retinoblastoma protein (pRB) pathway is crucial in glioblastoma development.
Purpose of the Study:
- To identify novel plant-derived compounds targeting the pRB pathway for glioblastoma treatment.
- To develop an efficient drug delivery system for enhanced glioblastoma therapy.
Main Methods:
- Screened 691 plant extracts for anti-cancer properties.
- Utilized molecular docking to identify potent compounds against pRB pathway proteins.
- Encapsulated the lead compound, silymarin, into solid lipid nanoparticles (SLNPs).
- Assessed cytotoxicity and anti-migratory effects on glioblastoma cell lines (U87, U251).
Main Results:
- Silymarin (Sil) was identified as a potent inhibitor of CDK4.
- SLNP-encapsulated silymarin (SLNP-Sil) demonstrated significant reduction in glioblastoma cell viability and migration.
- SLNP-Sil showed negligible toxicity to normal HEK-293 cells.
Conclusions:
- Silymarin and SLNP-Sil represent promising therapeutic strategies for glioblastoma.
- Further in vivo validation is warranted to confirm efficacy in preclinical models.
More Related Videos
14:10Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
Published on: December 15, 2010
07:25Author Spotlight: Multimodal Imaging Strategies for Optimizing Drug Delivery and Early Detection in Glioblastoma Treatment
Published on: March 1, 2024
